Related Experiment Video
Updated: Feb 13, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
Clinical outcomes after acute myocardial infarction according to a novel stratification system linked to a
Kei Yamamoto1, Kenichi Sakakura1, Naoyuki Akashi1
1Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Insights
A new risk classification for acute myocardial infarction (AMI) patients in cardiac rehabilitation shows significant differences in hospital stay and major adverse cardiac events (MACE) across low, intermediate, and high-risk groups.
Area of Science:
- Cardiology
- Clinical Research
- Rehabilitation Medicine
Background:
- Establishing a risk classification for acute myocardial infarction (AMI) patients undergoing cardiac rehabilitation is crucial.
- Previous risk stratification models for AMI rehabilitation have not been widely established.
Purpose of the Study:
- To introduce and validate a novel risk classification system for patients with acute myocardial infarction (AMI).
- To assess the correlation between risk groups and clinical outcomes, including hospital stay duration and major adverse cardiac events (MACE).
Main Methods:
- 292 AMI patients were categorized into low (L), intermediate (I), and high (H) risk groups.
- The primary endpoint was major adverse cardiac events (MACE): cardiac death, non-fatal AMI, stent thrombosis, and ischemia-driven target vessel revascularization.
- Follow-up was conducted for a mean period of 252 days.
Main Results:
- Coronary care unit (CCU) and hospital stays were shortest in the L-risk group and longest in the H-risk group (p<0.001).
- Major adverse cardiac events (MACE) incidence was significantly higher in the H-risk group (26.8%) compared to the I-risk (5.6%) and L-risk (1.9%) groups (p<0.001).
Conclusions:
- The developed risk classification system effectively differentiates AMI patients based on hospital stay duration.
- The system demonstrates significant correlations with major adverse cardiac events (MACE), supporting its clinical validity for cardiac rehabilitation programs.
Background:
A risk classification of acute myocardial infarction (AMI) linked to a rehabilitation program has not been established.
Methods:
We allocated 292 patients with AMI into the low- (L) (n=108), intermediate- (I) (n=72), and high- (H) (n=112) risk groups according to our original risk classification. The primary endpoint was major adverse cardiac events (MACE), defined as the composite of cardiac death, non-fatal AMI, stent thrombosis, and ischemia-driven target vessel revascularization. The mean follow-up period was 252 days.
Results:
The length of coronary care unit (CCU) stay and hospital stay was shortest in the L-risk group (CCU stay, 1.0±1.0 days; hospital stay, 5.6±3.2 days), followed by the I-risk group (CCU stay, 2.3±1.8 days; hospital stay, 8.1±2.7 days), and longest in the H-risk group (CCU stay, 5.1±5.0 days; hospital stay, 14.6±12.6 days) (p<0.001). MACE were most frequently observed in the H-risk group (26.8%), followed by the I-risk group (5.6%), and least in the L-risk group (1.9%) (p<0.001).
Conclusions:
The lengths of hospital stay and CCU stay were significantly shortest in the L-risk group, followed by the I-risk group, and longest in the H-risk group. MACE were most frequently observed in the H-risk group, followed by the I-risk group, and least in the L-risk group. These results support the validity of our new classification system.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...

